While the "will they or won't they" battle for Illumina (ILMN) is certainly the biggest headline-grabber for Roche (RHHBY.PK) right now, this Swiss giant is also seeing respectable progress in the business. Though I believe Roche remains one of the best long-term picks in healthcare, the relative performance of the shares no longer leaves it as the cheapest option in the sector.
Q1 - Steady As She Goes
Like many European companies, Roche isn't exactly geared to focus on quarterly performance. Nevertheless, revenue rose 2% in constant currency (down 1% in Swiss francs and up 1% in U.S. dollars) and actually beat most analysts' expectations though different sources report different numbers for the average sales estimate.
Read the full article here:
Steady As She Goes For Roche
No comments:
Post a Comment